Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms

Go online to PeerView.com/HZN860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and
non-BCMA treatment options has quickly changed the clinical
conversation for modern multiple myeloma (MM) management. Are you
prepared for the new “ABCs” of myeloma care? Find out by accessing
this PeerView MasterClass and Case Forum event developed in
collaboration with the HealthTree Foundation for Multiple Myeloma
and recorded at the 2023 ASCO Annual Meeting. During this activity,
our experts provide insights and case-based guidance on therapy
selection, dosing, scheduling, and management of treatment-related
AEs with CD38 antibodies and BCMA platforms in MM. Learn the
real-world “ABCs” of treatment innovation in MM, and take your
patient care to the next level! Upon completion of this activity,
participants should be better able to: Summarize the unique MOA and
safety/efficacy evidence supporting the use of CD38 and
BCMA-targeting antibodies, CAR-T therapy, and other innovative
compounds across multiple myeloma treatment settings; Develop
personalized upfront and sequential treatment plans with innovative
antibody and immunotherapy platforms, based on relevant prognostic
information and safety considerations; and Address practical
aspects of multiple myeloma care when using antibody and
immunotherapy platforms, including dosing, scheduling, patient
referral to specialized care, education, counseling, and unique
treatment-related toxicities